Published 17 days ago • loading... • Updated 17 days ago

This biotech name is evolving into a major obesity play. How to trade it with options

Summary by CNBC

Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.

Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.

17 days ago·United States

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated16 days agoBias Distribution

100% Center

100% Center

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

CNBC broke the news in United States 17 days ago on Wednesday, December 17, 2025.

Sources are mostly out of (0)

Amgen replaces declining Enbrel revenue with growth from the MariTide obesity program, Horizon rare-disease assets, and next-generation oncology, supported by over $10 billion free cash flow.